Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 03:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Cervical Ripening Before Induction of Labour at Term: a Randomised Comparison of Prostin vs Propess
NCT00545194 · Institut National de la Santé Et de la Recherche Médicale, France · PHASE3 · withdrawn · last registry update 2025-09-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No participants enrolled” | – | Registry record, Institut National de la Santé Et de la Recherche Médicale, France |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTGER1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-02-24Phase 3 first posted: Udayana University, Bilateral ESPB: Ropivacaine 0.375% + Dexamethasone 5mg + Bilateral ESPB: Ropivacaine 0.375% (NCT07429708)
- 2026-01-26Results posted on the registry: Mayo Clinic, a drug against PTGER1 (NCT05972486)
- 2025-12-18Results posted on the registry: Bright Uro, a drug against PTGER1 (NCT05959655)
- 2025-12-11Phase 3 first posted: Third Military Medical University, Lubiprostone + Polyethylene glycol (PEG ) (NCT07277907)
- 2025-04-09Results posted on the registry: Mayo Clinic, a drug against PTGER1 (NCT05199233)
- 2025-01-17Also stopped (terminated): Hospital Kemaman, Intravaginal prostaglandin E2 (NCT05622968)
- 2024-12-27Results posted on the registry: Mayo Clinic, a drug against PTGER1 (NCT04743973)
- 2024-11-21Also stopped (terminated): CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Alprostadil liposome injection (NCT05475717)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision